Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) fell 12% Monday to $2.87 after the FDA put a clinical hold on a phase III study of its autologous cell therapy for recessive dystrophic epidermolysis bullosa (RDEB), a trial that had initially been slated to start by mid-2019.